Highlights
Baseline fatigue is not merely a common symptom but a potent predictor of severe (grade 3+), life-threatening (grade 4+), and fatal (grade 5) adverse events in patients undergoing systemic cancer therapy.
There is a clear dose-response correlation; patients reporting severe baseline fatigue face an approximately five-fold increased risk of fatal toxic effects compared to those with minimal or no fatigue.
